EPI E Z PEN JR (epinephrine) by Viatris is adrenergic alpha-agonists [moa]. Approved for alpha-adrenergic agonist [epc]. First approved in 1987.
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
EPI E Z PEN JR is an intramuscular injectable epinephrine auto-injector approved in 1987 for pediatric emergency treatment of anaphylaxis and severe allergic reactions. It works as an alpha-adrenergic agonist, rapidly stimulating sympathetic nervous system receptors to reverse life-threatening allergic symptoms. This junior-dosed formulation is designed for children and smaller patients requiring lower epinephrine doses than adult versions.
With LOE approaching and moderate competitive pressure (45/100), expect consolidation of brand team focus toward generic transition and portfolio optimization rather than growth initiatives.
Adrenergic alpha-Agonists
alpha-Adrenergic Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Pharmacokinetics and Safety of a Single Dose of Epinephrine Nasal Spray in Paediatric Allergy Patients
Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Hemodynamic Effects of Norepinephrine Reduction on Critical Closing Pressure in Distributive Shock
Pneumatic Leg Compression and Norepinephrine Requirements in Patients Having Non-cardiac Surgery
Worked on EPI E Z PEN JR at Viatris? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on EPI E Z PEN JR offers limited career growth opportunity in a declining product lifecycle; roles are primarily defensive, focused on market share retention, provider relations, and transition planning ahead of generic entry. This assignment is best suited for professionals seeking experience in LOE management, portfolio optimization, or regulatory/compliance expertise rather than launching or scaling products.